Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Contineum Therapeutics (CTNM) Shares Issued (2023 - 2025)

Contineum Therapeutics has reported Shares Issued over the past 3 years, most recently at -$48000.0 for Q4 2025.

  • Quarterly results put Shares Issued at -$48000.0 for Q4 2025, down 112.47% from a year ago — trailing twelve months through Dec 2025 was $19.0 million (up 117.65% YoY), and the annual figure for FY2025 was $219000.0, down 43.12%.
  • Shares Issued for Q4 2025 was -$48000.0 at Contineum Therapeutics, down from $19.0 million in the prior quarter.
  • Over the last five years, Shares Issued for CTNM hit a ceiling of $19.0 million in Q3 2025 and a floor of -$107.9 million in Q2 2024.
  • Median Shares Issued over the past 3 years was $8000.0 (2023), compared with a mean of -$8.0 million.
  • Peak annual rise in Shares Issued hit 1425.0% in 2024, while the deepest fall reached 1348650.0% in 2024.
  • Contineum Therapeutics' Shares Issued stood at -$109000.0 in 2023, then soared by 453.21% to $385000.0 in 2024, then plummeted by 112.47% to -$48000.0 in 2025.
  • The last three reported values for Shares Issued were -$48000.0 (Q4 2025), $19.0 million (Q3 2025), and -$24000.0 (Q2 2025) per Business Quant data.